Keros Therapeutics Inc is a clinical-stage biopharmaceutical company operating across the United States. The company focuses on the development and commercialisation of transformative treatments for patients suffering from severe diseases.
Operating in the biopharmaceutical industry, Keros Therapeutics Inc develops novel treatments targeting haematological, cardiovascular and pulmonary disorders with unmet medical need. The company’s pipeline includes multiple product candidates aimed at unlocking therapeutic benefits, including KER-012, a lead product candidate for treating pulmonary arterial hypertension.
Stay up to date on the share price of KROS by adding it to your eToro watchlist.